Page 180 - Read Online

Dastidar et al. Vessel Plus 2020;4:14 I http://dx.doi.org/10.20517/2574-1209.2019.36 Page 27 of 29

138. Guo S, Lin CM, Xu Z, Miao L, Wang Y, et al. Co-delivery of cisplatin and rapamycin for enhanced anticancer therapy through synergistic
effects and microenvironment modulation. ACS Nano 2014;8:4996-5009.
139. US-FDA. FDA broadens afatinib indication to previously untreated, metastatic NSCLC with other non-resistant EGFR mutations.
Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-broadens-afatinib-indication-previously-untreated-
metastatic-nsclc-other-non-resistant-egfr [Last accessed on 12 Apr 2020]
140. US-FDA. FDA approves pembrolizumab plus axitinib for advanced renal cell carcinoma. Available from: https://www.fda.gov/drugs/
drug-approvals-and-databases/fda-approves-pembrolizumab-plus-axitinib-advanced-renal-cell-carcinoma [Last accessed on 12 Apr 2020]
141. US-FDA. Avastin Approval History. Available from: https://www.drugs.com/history/avastin.html [Last accessed on 12 Apr 2020]
142. US-FDA. FDA grants accelerated approval to bosutinib for treatment of newly-diagnosed PH+ CML. Available from: https://www.fda.
gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-bosutinib-treatment-newly-diagnosed-ph-cml [Last
accessed on 12 Apr 2020]
143. US-FDA. FDA Approved Uses of Cabozantinib. Available from: https://www.cancernetwork.com/thyroid-cancer/fda-approved-uses-
cabozantinib [Last accessed on 12 Apr 2020]
144. US-FDA. FDA approves cabozantinib for hepatocellular carcinoma. Available from: https://www.fda.gov/drugs/fda-approves-
cabozantinib-hepatocellular-carcinoma [Last accessed on 12 Apr 2020]
145. US-FDA. Information on Cetuximab (marketed as Erbitux). Available from: https://www.fda.gov/drugs/postmarket-drug-safety-
information-patients-and-providers/information-cetuximab-marketed-erbitux [Last accessed on 12 Apr 2020]
146. US-FDA. FDA Approves Crizotinib Capsules. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-
approves-crizotinib-capsules [Last accessed on 12 Apr 2020]
147. US-FDA. FDA approves dasatinib for pediatric patients with CML. Available from: https://www.fda.gov/drugs/resources-information-
approved-drugs/fda-approves-dasatinib-pediatric-patients-cml [Last accessed on 12 Apr 2020]
148. US-FDA. FDA approves Erlotinib (Tarceva) as first-line lung cancer therapy for certain patients. Available from: https://www.
cancernetwork.com/lung-cancer/fda-approves-erlotinib-tarceva-first-line-lung-cancer-therapy-certain-patients [Last accessed on 12 Apr
2020]
149. US-FDA. Everolimus (Afinitor). Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/everolimus-afinitor
[Last accessed on 12 Apr 2020]
150. Zeneca A. IRESSA® (gefitinib) approved by the U.S. Food and Drug Administration for first-line treatment of advanced EGFR mutation-
positive non-small cell lung cance. Available from: https://https://www.astrazeneca.com/media-centre/press-releases/2015/iressa-fda-
approved-non-small-cell-lung-cancer-treatment-13072015.html# [Last accessed on 12 Apr 2020]
151. US-FDA. FDA gives fast approval to gleevec in treatment of CML. Available from: https://www.cancernetwork.com/chronic-myeloid-
leukemia/fda-gives-fast-approval-gleevec-treatment-cml [Last accessed on 12 Apr 2020]
152. Ryan Q, Ibrahim A, Cohen MH, Johnson J, Ko CW, et al. FDA drug approval summary: lapatinib in combination with capecitabine for
previously treated metastatic breast cancer that overexpresses HER-2. Oncologist 2008;13:1114-9.
153. US-FDA. FDA approves lenalidomide for follicular and marginal zone lymphoma. Available from: https://www.fda.gov/drugs/resources-
information-approved-drugs/fda-approves-lenalidomide-follicular-and-marginal-zone-lymphoma [Last accessed on 12 Apr 2020]
154. US-FDA. FDA approves nilotinib for pediatric patients with newly diagnosed or resistant/intolerant Ph+ CML in chronic phase. Available
from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nilotinib-pediatric-patients-newly-diagnosed-or-
resistantintolerant-ph-cml-chronic [Last accessed on 12 Apr 2020]
155. US-FDA. FDA approves first treatment for patients with rare type of lung disease. Available from: https://www.fda.gov/news-events/
press-announcements/fda-approves-first-treatment-patients-rare-type-lung-disease [Last accessed on 12 Apr 2020]
156. US-FDA. FDA approves osimertinib for first-line treatment of metastatic NSCLC with most common EGFR mutations. Available from:
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-osimertinib-first-line-treatment-metastatic-nsclc-most-
common-egfr-mutations [Last accessed on 12 Apr 2020]
157. US-FDA. FDA approves Pazopanib for advanced soft-tissue sarcoma. Available from: https://www.ascopost.com/issues/may-15-2012/
fda-approves-pazopanib-for-advanced-soft-tissue-sarcoma/ [Last accessed on 12 Apr 2020]
158. US-FDA. Ponatinib (marketed as Iclusig) Informaton. Available from: https://www.fda.gov/drugs/postmarket-drug-safety-information-
patients-and-providers/ponatinib-marketed-iclusig-informaton [Last accessed on 12 Apr 2020]
159. US-FDA. FDA approves ramucirumab for hepatocellular carcinoma. Available from: https://www.fda.gov/drugs/resources-information-
approved-drugs/fda-approves-ramucirumab-hepatocellular-carcinoma [Last accessed on 12 Apr 2020]
160. US-FDA. Regorafenib becomes first FDA-approved drug for liver cancer in nearly a decade. Available from: https://www.cancer.gov/
news-events/cancer-currents-blog/2017/fda-regorafenib-liver [Last accessed on 12 Apr 2020]
161. Kane RC, Farrell AT, Saber H, Tang S, Williams G, et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res
2006;12:7271-8.
162. US-FDA. FDA approves sunitinib malate for adjuvant treatment of renal cell carcinoma. Available from: https://www.fda.gov/drugs/
resources-information-approved-drugs/fda-approves-sunitinib-malate-adjuvant-treatment-renal-cell-carcinoma [Last accessed on 12 Apr
2020]
163. Kwitkowski VE, Prowell TM, Ibrahim A, Farrell AT, Justice R, et al. FDA approval summary: temsirolimus as treatment for advanced
renal cell carcinoma. Oncologist 2010;15:428-35.
164. US-FDA. Thalidomide OK’d for multiple myeloma: FDA approves thalidomide with strict rules to prevent birth defects. Available from:
https://www.webmd.com/cancer/multiple-myeloma/news/20060526/thalidomide-okd-for-multiple-myeloma [Last accessed on 12 Apr